Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
Keep the sparks coming! Delegates of the conference have access to on-demand content until the end of October 2021.
This updated edition is a great reference for anyone working in multinational product development and marketing.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 26 April 2013 | By Alexander Gaffney, RAC,
The European Medicines Agency (EMA) announced this week that it has released its first-ever list of products that must be adorned with a new symbol first announced earlier this year that is meant to convey that the products have not yet been sufficiently assessed in a postmarketing setting.
The regulation requiring the symbol was announced in March 2013, and is binding on and in all Member States of the EU.
The symbol itself is supposed to be proportional to the text it accompanies, with each side of the triangle no smaller than 5 mm in length, and is intended to allow patients and healthcare professionals to easily and quickly identify which products are subject to additional monitoring to allow them to report suspected adverse events.
The rule comes into effect on 1 September 2013, and will apply to all non-generic medicinal products authorized after 1 January 2013, including biological medicinal products. Also included are all products approved before 1 January 2013 that are subject to additional monitoring, which must have the symbols on their packaging by 31 December 2013. Extensions may be granted on a case-by-case basis as requested if the sponsor can show that the change would "unduly affect the appropriate and continued supply of the medicinal product."
Existing stock "produced, packaged and labeled" before 1 January 2014 can be marketed even without the black symbol "until stocks are exhausted," the regulation states.
EMA has just published the first list of all medicines that will be required to be adorned with the black symbol, which includes a veritable group of recently-approved medications, including Pfizer's Bosulif and Champix, Eli Lilly's Amyvid, GlaxoSmithKline's Belysta, Takeda's Edarbi, Bristol-Myers Squibb's Eliquis, uniQure's Glybera, Novartis's Gilenya, and Elan's Tysarbi, to name but a few.
EMA said it hopes that the triangle will promote greater adverse reporting for new medicines, whose clinical trials often are not able to identify all potential safety issues that will eventually affect a given product. By keeping a closer eye on potential events, EMA said it will be able to warn consumers about safety issues sooner than before.
EMA Notice on Black Triangle
Tags: EU
Regulatory Focus newsletters
All the biggest regulatory news and happenings.